Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)

HA. Ghofrani, E. Grünig, P. Jansa, D. Langleben, S. Rosenkranz, IR. Preston, F. Rahaghi, N. Sood, D. Busse, C. Meier, M. Humbert,

. 2020 ; 10 (3) : 2045894020942121. [pub] 20200716

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20021971

Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present findings from patients who were receiving combined riociguat plus endothelin receptor antagonists or non-intravenous prostanoids in the randomized, placebo-controlled PATENT-1 study and its open-label extension (PATENT-2). Moreover, we include new data from patients receiving early sequential combination therapy (three to six months of endothelin receptor antagonist treatment) or long-term background endothelin receptor antagonist therapy (>6 months). Patients were randomized to riociguat 2.5 mg-maximum (N = 131 pretreated patients) and placebo (N = 60 pretreated patients). Riociguat improved 6-min walking distance (PATENT-1 primary endpoint), functional capacity, and hemodynamics after 12 weeks in pretreated patients. The placebo-corrected changes in 6-min walking distance were +24 m in endothelin receptor antagonist-pretreated patients and +106 m in the small group of prostanoid-pretreated patients. In the early sequential combination and long-term background endothelin receptor antagonist groups, the placebo-corrected changes in 6-min walking distance were +65 m (95% CI: 17 to 113 m) and +13 m (95% CI: -8 to 33 m), respectively. In conclusion, these data suggest that early sequential combination of an endothelin receptor antagonist plus riociguat is a feasible treatment option. Both early sequential therapy and long-term background endothelin receptor antagonist plus riociguat were well tolerated in the PATENT studies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20021971
003      
CZ-PrNML
005      
20210208140905.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2045894020942121 $2 doi
035    __
$a (PubMed)32728421
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Center, Member of German Center for Lung Research, Giessen, Germany. Department of Medicine, Imperial College London, London, UK.
245    10
$a Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies) / $c HA. Ghofrani, E. Grünig, P. Jansa, D. Langleben, S. Rosenkranz, IR. Preston, F. Rahaghi, N. Sood, D. Busse, C. Meier, M. Humbert,
520    9_
$a Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present findings from patients who were receiving combined riociguat plus endothelin receptor antagonists or non-intravenous prostanoids in the randomized, placebo-controlled PATENT-1 study and its open-label extension (PATENT-2). Moreover, we include new data from patients receiving early sequential combination therapy (three to six months of endothelin receptor antagonist treatment) or long-term background endothelin receptor antagonist therapy (>6 months). Patients were randomized to riociguat 2.5 mg-maximum (N = 131 pretreated patients) and placebo (N = 60 pretreated patients). Riociguat improved 6-min walking distance (PATENT-1 primary endpoint), functional capacity, and hemodynamics after 12 weeks in pretreated patients. The placebo-corrected changes in 6-min walking distance were +24 m in endothelin receptor antagonist-pretreated patients and +106 m in the small group of prostanoid-pretreated patients. In the early sequential combination and long-term background endothelin receptor antagonist groups, the placebo-corrected changes in 6-min walking distance were +65 m (95% CI: 17 to 113 m) and +13 m (95% CI: -8 to 33 m), respectively. In conclusion, these data suggest that early sequential combination of an endothelin receptor antagonist plus riociguat is a feasible treatment option. Both early sequential therapy and long-term background endothelin receptor antagonist plus riociguat were well tolerated in the PATENT studies.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Grünig, Ekkehard $u Center for Pulmonary Hypertension, Thoraxklinic, University Hospital Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
700    1_
$a Jansa, Pavel $u First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Langleben, David $u Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
700    1_
$a Rosenkranz, Stephan $u Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Köln, Germany.
700    1_
$a Preston, Ioana R $u Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.
700    1_
$a Rahaghi, Franck $u Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Florida, Weston, FL, USA.
700    1_
$a Sood, Namita $u The Lung Center, The Ohio State University, Columbus, OH, USA.
700    1_
$a Busse, Dennis $u Chrestos Concept GmbH & Co. KG, Essen, Germany.
700    1_
$a Meier, Christian $u Bayer AG, Berlin, Germany.
700    1_
$a Humbert, Marc $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and Institut National de la Santé et de la Recherche Médicale Unité 999, Le Kremlin-Bicêtre, France.
773    0_
$w MED00200184 $t Pulmonary circulation $x 2045-8932 $g Roč. 10, č. 3 (2020), s. 2045894020942121
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32728421 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20210208140904 $b ABA008
999    __
$a ind $b bmc $g 1591679 $s 1112643
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 3 $d 2045894020942121 $e 20200716 $i 2045-8932 $m Pulmonary circulation $n Pulm Circ $x MED00200184
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace